First Time Loading...

Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.275 AUD -3.51% Market Closed
Updated: May 2, 2024

Paradigm Biopharmaceuticals Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Paradigm Biopharmaceuticals Ltd
Revenue Peer Comparison

Comparables:
IMM
MSB
CSL
CUV
TLX

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Revenue
AU$8.7m
CAGR 3-Years
29%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Revenue
AU$256.6k
CAGR 3-Years
-61%
CAGR 5-Years
-45%
CAGR 10-Years
-24%
Mesoblast Ltd
ASX:MSB
Revenue
$7.5m
CAGR 3-Years
-23%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Revenue
$14.2B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
10%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Revenue
AU$87.3m
CAGR 3-Years
31%
CAGR 5-Years
25%
CAGR 10-Years
42%
Telix Pharmaceuticals Ltd
ASX:TLX
Revenue
AU$502.5m
CAGR 3-Years
359%
CAGR 5-Years
381%
CAGR 10-Years
N/A

See Also

What is Paradigm Biopharmaceuticals Ltd's Revenue?
Revenue
8.7m AUD

Based on the financial report for Dec 31, 2023, Paradigm Biopharmaceuticals Ltd's Revenue amounts to 8.7m AUD.

What is Paradigm Biopharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 5Y
26%

Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Paradigm Biopharmaceuticals Ltd have been 29% over the past three years , 26% over the past five years .